GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Margin of Safety % (DCF Dividends Based)

Sino Biopharmaceutical (HKSE:01177) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 20, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Sino Biopharmaceutical's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.


Competitive Comparison of Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based) falls into.


;
;

Sino Biopharmaceutical Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Industry
Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Executives
Tse Ping 2101 Beneficial owner
Tse Eric S Y 2101 Beneficial owner
Cheng Cheung Ling 2101 Beneficial owner
True Merit Global Limited 2101 Beneficial owner
Tse Theresa Y Y 2101 Beneficial owner
Thousand Eagles Limited 2101 Beneficial owner
France Investment (china 1) Group Limited 2101 Beneficial owner
Remarkable Industries Limited 2101 Beneficial owner
Validated Profits Limited 2101 Beneficial owner

Sino Biopharmaceutical Headlines

No Headlines